RAD ONC FREEDOM Oncology Pain

About

Brief Summary

The investigators propose to conduct a study in medically refractory cancer pain patients utilizing radiosurgery to ablate the pituitary hypophysis, as well as neuromodulate the centromedian and parafascicular complexes within the thalami - the so-called triple target. This involves treating the pituitary hypophysis and thalamus to a dose of 90 Gy. These patients will have previously failed to achieve adequate pain control with opioid pain regimens and interventional approaches. The trial will involve a multidisciplinary approach involving radiation oncology, neurosurgery, palliative care, and medical oncology colleagues across UCLA.

Primary Purpose

Supportive care

Study Type

Interventional

Phase

N/A

Eligibility

Gender

All

Healthy Volunteers

No

Minimum Age

18 Years

Maximum Age

N/A

Inclusion Criteria:

Male or female ≥ 18 years of age on day of SRS treatment.
Documentation of insufficiently controlled mixed, complex cancer pain based on Brief Pain Inventory (BPI) >8/10 despite optimization of opioid regimen
Not eligible for or willing to undergo further pain-relieving interventions
Written informed consent (and assent when applicable) obtained from patient or patient's legal representative and ability for patient to comply with the study requirements and agree to undergo the study's SRS treatment plan.

Exclusion Criteria:

Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
Claustrophobia or inability to life flat
Inability to undergo routine imaging studies
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Current history of intracranial malignancy or brain metastasis
Any prior intracranial irradiation
Previous history of craniotomy, deep brain stimulation (DBS) or laser interstitial themal therapy (LITT).
Presence of intracranial hardware such as leads for DBS or any other material that may interfere with safe treatment.
Any comorbidity or condition which would limit full compliance with the protocol